Incyte (INCY) and Enable announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational mutant calreticulin selective monoclonal antibody, with Enable’s enFuse on-body delivery system. Under the terms of the agreement, Incyte will obtain a worldwide, exclusive license to use the enFuse technology with its mutCALR-targeted therapy in essential thrombocythemia and myelofibrosis, with the potential to expand to additional assets and indications. Incyte will pay Enable an upfront technology access fee, potential R&D milestones, commercial milestones and a transfer price for clinical and commercial supply of enFuse devices.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte announces Phase 3b TRuE-AD4 study met co-primary endpoints
- Incyte (INCY) Q3 Earnings Cheat Sheet
- Eli Lilly, Incyte report results from BRAVE-AA-PEDS trial
- Incyte’s Clinical Developments Show Promise Amidst Competitive Challenges and Uncertain Revenue Potential
- Cautious Optimism for Incyte’s Early-Stage Cancer Therapies: Hold Rating Pending Further Data